Kymab, a Sanofi company, specializes in the discovery and development of fully human monoclonal antibody drugs. Their proprietary antibody platform allows for the generation of a diverse range of human antibodies, maximizing the chances of finding drug candidates quickly and efficiently. With a deep pipeline of human antibody-based therapies, Kymab focuses on developing treatments for various indications. Founded in 2010 and based in Cambridge, United Kingdom, Kymab was acquired by Sanofi in January 2021 for a valuation between $1100M and $1450M.